{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T06:01:36Z","timestamp":1793772096645,"version":"4.6.1"},"reference-count":102,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004033","name":"Johannes Gutenberg-Universit\u00e4t Mainz","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004033","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004895","name":"European Social Fund","doi-asserted-by":"publisher","award":["2019SD0129"],"award-info":[{"award-number":["2019SD0129"]}],"id":[{"id":"10.13039\/501100004895","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013060","name":"European Molecular Biology Laboratory","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","award":["2018FGI0025"],"award-info":[{"award-number":["2018FGI0025"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008769","name":"Julius-Maximilians-Universit\u00e4t W\u00fcrzburg","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008769","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["13XP5049"],"award-info":[{"award-number":["13XP5049"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.jconrel.2022.05.060","type":"journal-article","created":{"date-parts":[[2022,6,28]],"date-time":"2022-06-28T23:56:07Z","timestamp":1656460567000},"page":"881-892","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Polymer selection impacts the pharmaceutical profile of site-specifically conjugated Interferon-\u03b12a"],"prefix":"10.1016","volume":"348","author":[{"given":"Niklas","family":"Hauptstein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paria","family":"Pouyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Wittwer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gizem","family":"Cinar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Scherf-Clavel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Raschig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Licha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tessa","family":"L\u00fchmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivo","family":"Nischang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich S.","family":"Schubert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian K.","family":"Pfaller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rainer","family":"Haag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenz","family":"Meinel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2022.05.060_bb0005","doi-asserted-by":"crossref","first-page":"3582","DOI":"10.1016\/S0021-9258(17)40292-4","article-title":"Effect of covalent attachment of polyethylene glycol on immunogenicity and circulating life of bovine liver catalase","volume":"252","author":"Abuchowski","year":"1977","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jconrel.2022.05.060_bb0010","doi-asserted-by":"crossref","first-page":"3578","DOI":"10.1016\/S0021-9258(17)40291-2","article-title":"Alteration of immunological properties of bovine serum albumin by covalent attachment of polyethylene glycol","volume":"252","author":"Abuchowski","year":"1977","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jconrel.2022.05.060_bb0015","doi-asserted-by":"crossref","DOI":"10.1126\/science.abd4585","article-title":"Autoantibodies against type I IFNs in patients with life-threatening COVID-19","volume":"370","author":"Bastard","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.jconrel.2022.05.060_bb0020","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/nrd1033","article-title":"Effect of pegylation on pharmaceuticals","volume":"2","author":"Harris","year":"2003","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jconrel.2022.05.060_bb0025","doi-asserted-by":"crossref","first-page":"6288","DOI":"10.1002\/anie.200902672","article-title":"Poly(ethylene glycol) in drug delivery: pros and cons as well as potential alternatives","volume":"49","author":"Knop","year":"2010","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.jconrel.2022.05.060_bb0030","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1067\/mcp.2000.110973","article-title":"Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C intervention therapy group","volume":"68","author":"Glue","year":"2000","journal-title":"Clin. Pharmacol. Ther."},{"issue":"Suppl. 1","key":"10.1016\/j.jconrel.2022.05.060_bb0035","first-page":"23","article-title":"Pharmacokinetics of peginterferons","volume":"23","author":"Zeuzem","year":"2003","journal-title":"Semin. Liver Dis."},{"key":"10.1016\/j.jconrel.2022.05.060_bb0040","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1038\/nrd2422","article-title":"Interferons at age 50: past, current and future impact on biomedicine","volume":"6","author":"Borden","year":"2007","journal-title":"Nat. Rev. Drug Discov."},{"issue":"3","key":"10.1016\/j.jconrel.2022.05.060_bb0045","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.jfma.2020.09.018","article-title":"Ropeginterferon Alfa-2b administered every two weeks for patients with genotype 2 chronic hepatitis C","volume":"120","author":"Hsu","year":"2020","journal-title":"J. Formosan Med. Assoc."},{"key":"10.1016\/j.jconrel.2022.05.060_bb0050","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1002\/jps.24353","article-title":"Optimal PEGylation can improve the exposure of interferon in the lungs following pulmonary administration","volume":"104","author":"McLeod","year":"2015","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2022.05.060_bb0055","doi-asserted-by":"crossref","first-page":"S103","DOI":"10.1002\/hep.22956","article-title":"Benefits and risks of interferon therapy for hepatitis B","volume":"49","author":"Perrillo","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.jconrel.2022.05.060_bb0060","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/imr.12001","article-title":"Structural and dynamic determinants of type I interferon receptor assembly and their functional interpretation","volume":"250","author":"Piehler","year":"2012","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.jconrel.2022.05.060_bb0065","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/S0169-409X(02)00028-5","article-title":"Use of peginterferon alfa-2a (40 KD) (Pegasys\u00ae) for the treatment of hepatitis C","volume":"54","author":"Rajender Reddy","year":"2002","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2022.05.060_bb0070","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1089\/jir.2013.0158","article-title":"How type I interferons work in multiple sclerosis and other diseases: some unexpected mechanisms","volume":"34","author":"Reder","year":"2014","journal-title":"J. Interf. Cytokine Res."},{"key":"10.1016\/j.jconrel.2022.05.060_bb0075","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1021\/bc049713n","article-title":"Highly potent interferon \u03b1-2 conjugate created using site-specific PEGylation","volume":"16","author":"Rosendahl","year":"2005","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.jconrel.2022.05.060_bb0080","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.it.2017.05.005","article-title":"Type I interferon in chronic virus infection and cancer","volume":"38","author":"Snell","year":"2017","journal-title":"Trends Immunol."},{"key":"10.1016\/j.jconrel.2022.05.060_bb0085","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.cell.2011.06.048","article-title":"Structural linkage between ligand discrimination and receptor activation by type I interferons","volume":"146","author":"Thomas","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.jconrel.2022.05.060_bb0090","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1159\/000045125","article-title":"Interferon therapy for chronic hepatitis C in hemodialysis patients: increased serum levels of interferon","volume":"80","author":"Uchihara","year":"1998","journal-title":"Nephron"},{"key":"10.1016\/j.jconrel.2022.05.060_bb0095","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S0169-409X(02)00027-3","article-title":"Structural and biological characterization of pegylated recombinant interferon alpha-2b and its therapeutic implications","volume":"54","author":"Wang","year":"2002","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2022.05.060_bb0100","doi-asserted-by":"crossref","first-page":"10634","DOI":"10.1021\/bi000617t","article-title":"Identification of the major positional isomer of pegylated interferon alpha-2b","volume":"39","author":"Wang","year":"2000","journal-title":"Biochemistry"},{"key":"10.1016\/j.jconrel.2022.05.060_bb0105","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1021\/bc000082g","article-title":"Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C","volume":"12","author":"Bailon","year":"2001","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.jconrel.2022.05.060_bb0110","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ejpb.2022.02.006","article-title":"Bioconjugation strategies and clinical implications of interferon-bioconjugates","volume":"172","author":"Hauptstein","year":"2022","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jconrel.2022.05.060_bb0115","author":"EMA"},{"key":"10.1016\/j.jconrel.2022.05.060_bb0120","author":"EMA"},{"key":"10.1016\/j.jconrel.2022.05.060_bb0125","author":"EMA"},{"key":"10.1016\/j.jconrel.2022.05.060_bb0130","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.addr.2020.07.024","article-title":"Anti-PEG antibodies: properties, formation, testing and role in adverse immune reactions to PEGylated nano-biopharmaceuticals","volume":"154-155","author":"Kozma","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2022.05.060_bb0135","series-title":"Polymer-Protein Conjugates","first-page":"103","article-title":"5 - Immunological responses to PEGylated proteins: anti-PEG antibodies","author":"Elsadek","year":"2020"},{"key":"10.1016\/j.jconrel.2022.05.060_bb0140","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/S1046-5928(03)00055-X","article-title":"Isolation, structural characterization, and antiviral activity of positional isomers of monopegylated interferon \u03b1-2a (PEGASYS)","volume":"30","author":"Foser","year":"2003","journal-title":"Protein Expr. Purif."},{"key":"10.1016\/j.jconrel.2022.05.060_bb0145","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1002\/wnan.1339","article-title":"Anti-PEG immunity: emergence, characteristics, and unaddressed questions","volume":"7","author":"Yang","year":"2015","journal-title":"WIREs Nanomed. Nanobiotechnol."},{"key":"10.1016\/j.jconrel.2022.05.060_bb0150","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.matt.2019.11.011","article-title":"Site-selective protein modification: from functionalized proteins to functional biomaterials","volume":"2","author":"Shadish","year":"2020","journal-title":"Matter"},{"key":"10.1016\/j.jconrel.2022.05.060_bb0155","author":"EMA"},{"key":"10.1016\/j.jconrel.2022.05.060_bb0160","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/cei.13420","article-title":"Comparison of elapegademase and pegademase in ADA-deficient patients and mice","volume":"200","author":"Murguia-Favela","year":"2020","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.jconrel.2022.05.060_bb0165","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/S0169-409X(03)00110-8","article-title":"Pegaspargase: a review of clinical studies","volume":"55","author":"Graham","year":"2003","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2022.05.060_bb0175","series-title":"Methods Enzymol","first-page":"55","article-title":"Chapter Three - Intense PEGylation of enzyme surfaces: Relevant stabilizing effects","author":"Moreno-P\u00e9rez","year":"2016"},{"key":"10.1016\/j.jconrel.2022.05.060_bb0180","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s40259-015-0127-4","article-title":"Design rationale and development approach for pegfilgrastim as a long-acting granulocyte colony-stimulating factor","volume":"29","author":"Arvedson","year":"2015","journal-title":"BioDrugs"},{"key":"10.1016\/j.jconrel.2022.05.060_bb0185","doi-asserted-by":"crossref","first-page":"315","DOI":"10.2165\/00063030-200822050-00004","article-title":"The impact of PEGylation on biological therapies","volume":"22","author":"Veronese","year":"2008","journal-title":"Biodrugs"},{"key":"10.1016\/j.jconrel.2022.05.060_bb0190","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1038\/s41467-020-14757-4","article-title":"Cysteine-specific protein multi-functionalization and disulfide bridging using 3-bromo-5-methylene pyrrolones","volume":"11","author":"Zhang","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2022.05.060_bb0195","doi-asserted-by":"crossref","first-page":"14257","DOI":"10.1002\/chem.202001992","article-title":"Tyrosine conjugation methods for protein labelling","volume":"26","author":"Alvarez Dorta","year":"2020","journal-title":"Chemistry"},{"key":"10.1016\/j.jconrel.2022.05.060_bb0200","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1021\/bm101272g","article-title":"Arginine-specific modification of proteins with polyethylene glycol","volume":"12","author":"Gauthier","year":"2011","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.jconrel.2022.05.060_bb0205","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1039\/C8SC03355B","article-title":"Site-selective protein conjugation at histidine","volume":"10","author":"Peciak","year":"2019","journal-title":"Chem. Sci."},{"issue":"6","key":"10.1016\/j.jconrel.2022.05.060_bb0210","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1016\/j.xphs.2021.10.032","article-title":"Linear polyglycerol for N-terminal-selective modification of Interleukin-4","volume":"111","author":"Tully","year":"2021","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2022.05.060_bb0215","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1021\/acs.biomac.0c01627","article-title":"Polyglycerol for half-life extension of proteins\u2014alternative to PEGylation?","volume":"22","author":"Tully","year":"2021","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.jconrel.2022.05.060_bb0220","doi-asserted-by":"crossref","first-page":"3169","DOI":"10.1073\/pnas.1016863108","article-title":"Sortase-catalyzed transformations that improve the properties of cytokines","volume":"108","author":"Popp","year":"2011","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"1","key":"10.1016\/j.jconrel.2022.05.060_bb0225","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1021\/acs.bioconjchem.1c00495","article-title":"Chemo-enzymatic PEGylation\/POxylation of murine interleukin-4","volume":"33","author":"Haas","year":"2021","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.jconrel.2022.05.060_bb0230","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1038\/nchembio.2007.31","article-title":"Sortagging: a versatile method for protein labeling","volume":"3","author":"Popp","year":"2007","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.jconrel.2022.05.060_bb0235","series-title":"Antibody-Drug Conjugates: Methods and Protocols","first-page":"71","article-title":"Transglutaminase-mediated conjugations","author":"Anami","year":"2020"},{"key":"10.1016\/j.jconrel.2022.05.060_bb0240","series-title":"Enzyme-Mediated Ligation Methods","first-page":"135","article-title":"Site-specific antibody\u2013drug conjugation using microbial transglutaminase","author":"Dickgiesser","year":"2019"},{"key":"10.1016\/j.jconrel.2022.05.060_bb0245","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1021\/bc400574z","article-title":"Transglutaminase-based chemo-enzymatic conjugation approach yields homogeneous antibody\u2013drug conjugates","volume":"25","author":"Dennler","year":"2014","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.jconrel.2022.05.060_bb0250","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.addr.2007.06.015","article-title":"Site-specific modification and PEGylation of pharmaceutical proteins mediated by transglutaminase","volume":"60","author":"Fontana","year":"2008","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2022.05.060_bb0255","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1093\/glycob\/cwl004","article-title":"GlycoPEGylation of recombinant therapeutic proteins produced in Escherichia coli","volume":"16","author":"DeFrees","year":"2006","journal-title":"Glycobiology"},{"key":"10.1016\/j.jconrel.2022.05.060_bb0260","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1182\/blood-2011-02-336172","article-title":"Prolonged half-life and preserved enzymatic properties of factor IX selectively PEGylated on native N-glycans in the activation peptide","volume":"118","author":"\u00d8stergaard","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.jconrel.2022.05.060_bb0265","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/s41573-018-0005-0","article-title":"Polymer\u2013drug conjugate therapeutics: advances, insights and prospects","volume":"18","author":"Ekladious","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jconrel.2022.05.060_bb0270","doi-asserted-by":"crossref","first-page":"25831","DOI":"10.3390\/ijms161025831","article-title":"Site-specific PEGylation of therapeutic proteins","volume":"16","author":"Dozier","year":"2015","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jconrel.2022.05.060_bb0275","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.xphs.2015.11.015","article-title":"PEGylation of biopharmaceuticals: a review of chemistry and nonclinical safety information of approved drugs","volume":"105","author":"Turecek","year":"2016","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2022.05.060_bb0280","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.cbpa.2015.08.009","article-title":"Protein\u2013polymer conjugation\u2014moving beyond PEGylation","volume":"28","author":"Qi","year":"2015","journal-title":"Curr. Opin. Chem. Biol."},{"key":"10.1016\/j.jconrel.2022.05.060_bb0285","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1021\/acsbiomaterials.5b00236","article-title":"Bio-orthogonal immobilization of fibroblast growth factor 2 for spatial controlled cell proliferation","volume":"1","author":"L\u00fchmann","year":"2015","journal-title":"ACS Biomater. Sci. Eng."},{"key":"10.1016\/j.jconrel.2022.05.060_bb0290","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.jsb.2014.02.009","article-title":"Decoration of silk fibroin by click chemistry for biomedical application","volume":"186","author":"Zhao","year":"2014","journal-title":"J. Struct. Biol."},{"key":"10.1016\/j.jconrel.2022.05.060_bb0295","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1002\/cbic.201500582","article-title":"Biocompatible azide\u2013alkyne \u201cclick\u201d reactions for surface decoration of glyco-engineered cells","volume":"17","author":"Gutmann","year":"2016","journal-title":"ChemBioChem"},{"key":"10.1016\/j.jconrel.2022.05.060_bb0300","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1002\/cbic.201600480","article-title":"Interleukin-4-clicked surfaces drive M2 macrophage polarization","volume":"17","author":"L\u00fchmann","year":"2016","journal-title":"ChemBioChem"},{"key":"10.1016\/j.jconrel.2022.05.060_bb0305","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s13036-016-0031-6","article-title":"Probing unnatural amino acid integration into enhanced green fluorescent protein by genetic code expansion with a high-throughput screening platform","volume":"10","author":"Wandrey","year":"2016","journal-title":"J. Biol. Eng."},{"key":"10.1016\/j.jconrel.2022.05.060_bb0310","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1021\/acsbiomaterials.6b00578","article-title":"Site-specific POxylation of interleukin-4","volume":"3","author":"L\u00fchmann","year":"2017","journal-title":"ACS Biomater. Sci. Eng."},{"key":"10.1016\/j.jconrel.2022.05.060_bb0315","first-page":"56616","article-title":"Site-directed immobilization of bone morphogenetic protein 2 to solid surfaces by click chemistry","author":"Siverino","year":"2018","journal-title":"J. Vis. Exp."},{"key":"10.1016\/j.jconrel.2022.05.060_bb0320","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1021\/acsbiomaterials.7b01016","article-title":"Site-specific conjugated insulin-like growth factor-I for anabolic therapy","volume":"4","author":"Wu","year":"2018","journal-title":"ACS Biomater. Sci. Eng."},{"key":"10.1016\/j.jconrel.2022.05.060_bb0325","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jconrel.2018.01.018","article-title":"Bioorthogonal strategies for site-directed decoration of biomaterials with therapeutic proteins","volume":"273","author":"Braun","year":"2018","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2022.05.060_bb0330","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jconrel.2018.04.009","article-title":"Bioresponsive release of insulin-like growth factor-I from its PEGylated conjugate","volume":"279","author":"Braun","year":"2018","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2022.05.060_bb0335","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1021\/acsbiomaterials.8b00865","article-title":"Metabolic glycoengineering of cell-derived matrices and cell surfaces: a combination of key principles and step-by-step procedures","volume":"5","author":"Gutmann","year":"2019","journal-title":"ACS Biomater. Sci. Eng."},{"key":"10.1016\/j.jconrel.2022.05.060_bb0340","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1021\/acsbiomaterials.9b01248","article-title":"Biodistribution of site-specific PEGylated fibroblast growth factor-2","volume":"6","author":"L\u00fchmann","year":"2020","journal-title":"ACS Biomater. Sci. Eng."},{"key":"10.1016\/j.jconrel.2022.05.060_bb0345","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.jconrel.2020.07.005","article-title":"Targeting interleukin-4 to the arthritic joint","volume":"326","author":"Spieler","year":"2020","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2022.05.060_bb0350","doi-asserted-by":"crossref","first-page":"4521","DOI":"10.1021\/acs.biomac.1c00775","article-title":"Molecular insights into site-specific interferon-\u03b12a bioconjugates originated from PEG, LPG, and PEtOx","volume":"22","author":"Hauptstein","year":"2021","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.jconrel.2022.05.060_bb0355","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.ejpb.2021.04.019","article-title":"Prolonged activity of exenatide: detailed comparison of site-specific linear polyglycerol- and poly(ethylene glycol)-conjugates","volume":"164","author":"Tully","year":"2021","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jconrel.2022.05.060_bb0360","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1111\/cea.12760","article-title":"Immediate-type hypersensitivity to polyethylene glycols: a review","volume":"46","author":"Wenande","year":"2016","journal-title":"Clin. Exp. Allergy"},{"key":"10.1016\/j.jconrel.2022.05.060_bb0365","article-title":"Immediate-type hypersensitivity to polyethylene glycol (PEG) including a PEG-containing COVID-19 vaccine revealed by intradermal testing","volume":"0","author":"Pickert","year":"2021","journal-title":"J Investig Allergol Clin Immunol"},{"key":"10.1016\/j.jconrel.2022.05.060_bb0370","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1038\/s42004-020-00369-y","article-title":"Structure of an anti-PEG antibody reveals an open ring that captures highly flexible PEG polymers","volume":"3","author":"Huckaby","year":"2020","journal-title":"Commun. Chem."},{"key":"10.1016\/j.jconrel.2022.05.060_bb0375","doi-asserted-by":"crossref","DOI":"10.3390\/polym12020298","article-title":"The importance of poly(ethylene glycol) alternatives for overcoming PEG immunogenicity in drug delivery and bioconjugation","volume":"12","author":"Hoang Thi","year":"2020","journal-title":"Polymers"},{"key":"10.1016\/j.jconrel.2022.05.060_bb0380","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1016\/S0006-3495(00)76713-0","article-title":"Size-distribution analysis of macromolecules by sedimentation velocity ultracentrifugation and Lamm equation modeling","volume":"78","author":"Schuck","year":"2000","journal-title":"Biophys. J."},{"key":"10.1016\/j.jconrel.2022.05.060_bb0385","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1016\/S0006-3495(02)75469-6","article-title":"Size-distribution analysis of proteins by analytical ultracentrifugation: strategies and application to model systems","volume":"82","author":"Schuck","year":"2002","journal-title":"Biophys. J."},{"key":"10.1016\/j.jconrel.2022.05.060_bb0390","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1021\/acs.analchem.6b03615","article-title":"Hydrodynamic analysis resolves the pharmaceutically-relevant absolute molar mass and solution properties of synthetic poly(ethylene glycol)s created by varying initiation sites","volume":"89","author":"Nischang","year":"2017","journal-title":"Anal. Chem."},{"key":"10.1016\/j.jconrel.2022.05.060_bb0395","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1021\/acs.macromol.7b02665","article-title":"POx as an alternative to PEG? A Hydrodynamic and light scattering study","volume":"51","author":"Grube","year":"2018","journal-title":"Macromolecules"},{"key":"10.1016\/j.jconrel.2022.05.060_bb0400","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0026221","article-title":"Density contrast sedimentation velocity for the determination of protein partial-specific volumes","volume":"6","author":"Brown","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.jconrel.2022.05.060_bb0405","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1007\/BF01496937","article-title":"Determination of the partial specific volume of conjugated proteins","volume":"267","author":"Durchschlag","year":"1989","journal-title":"Colloid Polym. Sci."},{"key":"10.1016\/j.jconrel.2022.05.060_bb0410","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1021\/bc049781+","article-title":"Structural and biophysical characterization of the 40 kDa PEG\u2212interferon-\u03b12a and its individual positional isomers","volume":"16","author":"Dhalluin","year":"2005","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.jconrel.2022.05.060_bb0415","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/s41557-020-0476-6","article-title":"Raising the ribosomal repertoire","volume":"12","author":"Reinkemeier","year":"2020","journal-title":"Nat. Chem."},{"key":"10.1016\/j.jconrel.2022.05.060_bb0420","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1002\/cbic.201200407","article-title":"Genetic encoding of a bicyclo[6.1.0]nonyne-charged amino acid enables fast cellular protein imaging by metal-free ligation","volume":"13","author":"Borrmann","year":"2012","journal-title":"Chembiochem"},{"key":"10.1016\/j.jconrel.2022.05.060_bb0430","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/pro.3703","article-title":"SimpleDSFviewer: a tool to analyze and view differential scanning fluorimetry data for characterizing protein thermal stability and interactions","volume":"29","author":"Sun","year":"2020","journal-title":"Protein Sci."},{"key":"10.1016\/j.jconrel.2022.05.060_bb0435","doi-asserted-by":"crossref","first-page":"S46","DOI":"10.1016\/j.vaccine.2005.01.117","article-title":"Adjuvant activity of interferon alpha: mechanism(s) of action","volume":"24","author":"Tovey","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.jconrel.2022.05.060_bb0440","author":"M\u00fcller"},{"key":"10.1016\/j.jconrel.2022.05.060_bb0445","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1021\/acs.biomac.0c01789","article-title":"Inhibition of herpes simplex virus type 1 attachment and infection by sulfated polyglycerols with different architectures","volume":"22","author":"Pouyan","year":"2021","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.jconrel.2022.05.060_bb0450","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1021\/acs.chemrev.5b00441","article-title":"Polymerization of ethylene oxide, propylene oxide, and other alkylene oxides: synthesis, novel polymer architectures, and bioconjugation","volume":"116","author":"Herzberger","year":"2016","journal-title":"Chem. Rev."},{"key":"10.1016\/j.jconrel.2022.05.060_bb0455","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.pep.2014.04.010","article-title":"High yield soluble bacterial expression and streamlined purification of recombinant human interferon \u03b1-2a","volume":"99","author":"Bis","year":"2014","journal-title":"Protein Expr. Purif."},{"key":"10.1016\/j.jconrel.2022.05.060_bb0460","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.1021\/bi00280a012","article-title":"pH-dependent polymerization of a human leukocyte interferon produced by recombinant deoxyribonucleic acid technology","volume":"22","author":"Shire","year":"1983","journal-title":"Biochemistry"},{"key":"10.1016\/j.jconrel.2022.05.060_bb0465","doi-asserted-by":"crossref","first-page":"13657","DOI":"10.1021\/acs.jpcb.1c07090","article-title":"Electrostatics drive oligomerization and aggregation of human interferon alpha-2a","volume":"125","author":"Pohl","year":"2021","journal-title":"J. Phys. Chem. B"},{"key":"10.1016\/j.jconrel.2022.05.060_bb0470","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/jps.22751","article-title":"Characterization of the self-association of human interferon-\u03b12b, Albinterferon-\u03b12b, and Pegasys","volume":"101","author":"Li","year":"2012","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2022.05.060_bb0475","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1002\/jps.21170","article-title":"Effect of PEGylation on the solution conformation of antibody fragments","volume":"97","author":"Lu","year":"2008","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2022.05.060_bb0480","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1021\/mp200470c","article-title":"Effect of PEGylation on protein hydrodynamics","volume":"9","author":"Gokarn","year":"2012","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2022.05.060_bb0485","doi-asserted-by":"crossref","first-page":"15805","DOI":"10.1021\/acs.analchem.1c03116","article-title":"Reincarnation of the analytical ultracentrifuge: emerging opportunities for nanomedicine","volume":"93","author":"Valderrama","year":"2021","journal-title":"Anal. Chem."},{"key":"10.1016\/j.jconrel.2022.05.060_bb0490","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1158\/1078-0432.CCR-16-1386","article-title":"A potent in vivo antitumor efficacy of novel recombinant type I interferon","volume":"23","author":"Zhang","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2022.05.060_bb0495","doi-asserted-by":"crossref","first-page":"7320","DOI":"10.1002\/adma.201503440","article-title":"Enhancing pharmacokinetics, tumor accumulation, and antitumor efficacy by elastin-like polypeptide fusion of interferon alpha","volume":"27","author":"Hu","year":"2015","journal-title":"Adv. Mater."},{"key":"10.1016\/j.jconrel.2022.05.060_bb0500","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.jconrel.2013.03.006","article-title":"PEGylation of interferon \u03b12 improves lymphatic exposure after subcutaneous and intravenous administration and improves antitumour efficacy against lymphatic breast cancer metastases","volume":"168","author":"Kaminskas","year":"2013","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2022.05.060_bb0505","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.yrtph.2014.05.019","article-title":"Pre-clinical toxicokinetics and safety study of M2ES, a PEGylated recombinant human endostatin, in rhesus monkeys","volume":"69","author":"Guo","year":"2014","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"10.1016\/j.jconrel.2022.05.060_bb0510","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1021\/bc050237q","article-title":"N-terminally PEGylated human interferon-\u03b2-1a with improved pharmacokinetic properties and in vivo efficacy in a melanoma angiogenesis model","volume":"17","author":"Baker","year":"2006","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.jconrel.2022.05.060_bb0515","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.pep.2003.11.004","article-title":"Expression, purification, and characterization of rat interferon-\u03b2, and preparation of an N-terminally PEGylated form with improved pharmacokinetic parameters","volume":"34","author":"Arduini","year":"2004","journal-title":"Protein Expr. Purif."},{"key":"10.1016\/j.jconrel.2022.05.060_bb0520","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1042\/BA20010001","article-title":"Purification and conformational properties of a human interferon alpha2b produced in Escherichia coli","volume":"33","author":"Beldarra\u00edn","year":"2001","journal-title":"Biotechnol. Appl. Biochem."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365922003819?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365922003819?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T16:39:08Z","timestamp":1759163948000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365922003819"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":102,"alternative-id":["S0168365922003819"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2022.05.060","relation":{"has-preprint":[{"id-type":"doi","id":"10.26434\/chemrxiv-2022-j85br","asserted-by":"object"}]},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Polymer selection impacts the pharmaceutical profile of site-specifically conjugated Interferon-\u03b12a","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2022.05.060","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}